COVID-19: Norway probing loss of life of two individuals who acquired Pfizer’s vaccine

Norway has launched a probe into the loss of life of two nursing residence residents who died after receiving COVID-19 vaccine developed by Pfizer and BioNTech.

It comes after a paediatric surgical procedure assistant in Portugal died two days after receiving Pfizer’s vaccine.

Medical Director of Norwegian Medicines Company Steiner Madsen stated in a press release, ”We have now to evaluate whether or not the vaccine is the reason for loss of life, or if it’s a coincidence that it occurred quickly after vaccination.”

The company is investigating the trigger the deaths collectively with Norway’s Nationwide Institute of Public Well being.

Madsen, nonetheless, famous that as people of advanced age are receiving COVID-19 vaccine in the first phase it’s doable that the deaths might be coincidental.

Earlier, Pfizer Inc’s CEO Albert Bourla had stated that the corporate is “not sure” if people who find themselves vaccinated in opposition to COVID-19 will be capable of transmit the lethal virus to others.

After Pfizer’s declare that its vaccine in opposition to COVID-19 vaccine is over 90 per cent efficient, some volunteers claimed that they suffered unwanted side effects just like to a flu jab.

Norway Prime Minister Erna Solberg stated on Sunday that recent restrictions might be imposed throughout the nation to curb the resurgence of the unfold of coronavirus. He had stated that nationwide ban might be imposed on serving alcohol in eating places and bars and other people is not going to be allowed to ask company residence.

Norway authorities is now additionally discouraging all journey for personal functions. It’s to be famous Norway had already imposed a number of the hardest journey restrictions in Europe as non-residents in Norway are required to indicate proof that they’re COVID-19 detrimental earlier than coming into the nation.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *